Component
Human amodiaquine and desethylamodiaquine pharmacokinetic exposure
Species, preparation, dose and limitations are retained on linked claims.
1 recorded relationships. Experimental role, claim status and evidence remain attached to each record.
How nutrients influence it
Every nutrient with a recorded effect on this component, credited to the nutrient that acted rather than the chapter that recorded it. Open a nutrient to see the findings and the conditions they were measured under.
Other things that act on it
Enzymes, hormones, genes, and other components with a recorded effect. These are not nutrients, so they do not count toward the arrows above. Each finding names the chapter that recorded it.
How nutrients reach it in more than one step
Chains of two or more recorded steps that end here, grouped by the nutrient they start from. Each step is a separate finding, so a chain is a route a mechanism could take, not proof that it does.
Tracing routes…
What it does
Every recorded relationship this component is part of, grouped by its role. Plain wording comes first; the technical statement follows.
What acts on it
In twenty healthy volunteers, concurrent Moringa leaf powder lowered amodiaquine Cmax, while seven-day pretreatment increased desethylamodiaquine Cmax and AUC; desethylamodiaquine AUC rose 40.4% with concurrent dosing and 188% after pretreatment.
Experimental context and source evidence
- dose
- Single amodiaquine 10 mg/kg with concurrent 3 g Moringa or after 3 g/day for seven days
- duration
- Concurrent dose or seven-day pretreatment
- evidence_access
- Primary PubMed abstract and indexed metadata reviewed. Full-text method details not stated here remain unresolved.
- evidence_scope
- literature_reviewed; model-specific source-derived curation
- experimental_model
- Twenty healthy adults in a three-period study
- limitations
- Pharmacokinetic changes may not translate directly to efficacy or toxicity; the open sequence and specific powder schedule limit generalization.
- nutrient_topic
- Moringa oleifera chapter; interacting nutrients, drugs, peptides and proteins retain their experimental settings. · Moringa oleifera
- organism
- Twenty healthy adults in a three-period study
- plain_language
- In twenty healthy volunteers, concurrent Moringa leaf powder lowered amodiaquine Cmax, while seven-day pretreatment increased desethylamodiaquine Cmax and AUC; desethylamodiaquine AUC rose 40.4% with concurrent dosing and 188% after pretreatment.
- primary_references
- Moringa oleifera leaf powder alters the pharmacokinetics of amodiaquine in healthy human volunteers. (2018). https://pubmed.ncbi.nlm.nih.gov/29920710/ DOI: 10.1111/jcpt.12725
- route
- Oral
- tissue
- Amodiaquine and desethylamodiaquine plasma pharmacokinetics
Moringa oleifera: mechanism of action and interactions (2026-09-20) · lines 189–198
Original AI-assisted source-specific curation with primary-study citations, model, exposure, route, duration, negative findings and limitations preserved. Not publisher full text. · supports · Twenty healthy adults in a three-period study · source_derived_draft · unverified_draft
## moringa-amodiaquine-pk-interaction In twenty healthy volunteers, concurrent Moringa leaf powder lowered amodiaquine Cmax, while seven-day pretreatment increased desethylamodiaquine Cmax and AUC; desethylamodiaquine AUC rose 40.4% with concurrent dosing and 188% after pretreatment. Model/species: Twenty healthy adults in a three-period study Tissue/system: Amodiaquine and desethylamodiaquine plasma pharmacokinetics Exposure: Single amodiaquine 10 mg/kg with concurrent 3 g Moringa or after 3 g/day for seven days Route: Oral Duration: Concurrent dose or seven-day pretreatment Limits: Pharmacokinetic changes may not translate directly to efficacy or toxicity; the open sequence and specific powder schedule limit generalization. Primary reference: Moringa oleifera leaf powder alters the pharmacokinetics of amodiaquine in healthy human volunteers. (2018). https://pubmed.ncbi.nlm.nih.gov/29920710/ DOI: 10.1111/jcpt.12725 Access: Primary PubMed abstract and indexed metadata reviewed. Full-text method details not stated here remain unresolved.
Complete structured claim and evidence
The events it takes part in
A mechanism often involves more than two components. These are the full events, with every participant and its role.
Situations it appears in
Low-supply and faulty-machinery situations recorded in the chapters where this component plays a part.
In the sources
Preserved passages that mention this component, quoted exactly. Open one to read it in context.
Open hypotheses
Proposed ideas that involve this component. They are labeled as hypotheses and do not change any recorded statement.
This is a research prototype built from draft material. It is not medical advice, and its statements still await verification against the original studies.